In this section of the General Tradeshow News Site, you'll find event-related news releases from PR Newswire. The releases are listed in chronological order and are archived by month and year.
- Preliminary results of phase 1 study demonstrate once-daily oral dosing of DS-3032 appears to be promising approach to treat relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)